newsfilter
← Latest News
Business Wire·

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today